Clinical trials: Inflammatory Disease
Rheumatoid Arthritis
Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)
The core and extension studies assessed the safety and efficacy of secukinumab when added to a background therapy in patients with active rheumatoid arthritis who are intolerant to or have had an inadequate response to anti-TNF-α…
- Trial name
- NURTURE 1 (NCT01350804)
- Testing
- AIN457, Abatacept
- Where
- 117 sites in United States, Brazil and 13 more
- Volunteers
- 551 people
- Sponsor
- Novartis Pharmaceuticals
Endometriosis
PGL5001 Proof of Concept Study in Inflammatory Endometriosis
This is a prospective, three-part (Part A1, Part A2 and Part B),Phase II study investigating the efficacy, safety, pharmacokinetics and pharmacodynamics of the JNK inhibitor PGL5001 orally administered for up to 5 months with…
- Trial name
- JADE (NCT01630252)
- Testing
- PGL5001
- Where
- Poland
- Volunteers
- 24 people
- Sponsor
- PregLem SA
Ulcerative Colitis
Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis
This study was designed to evaluate if subjects who achieve complete remission after 8 weeks of acute therapy with MMX mesalamine/mesalazine 4.8g/day given QD have better long-term outcomes and remain in remission longer compared…
- Trial name
- NCT01124149
- Testing
- MMX mesalamine/ mesalazine
- Where
- 105 sites in United States, Belgium and 13 more
- Volunteers
- 759 people
- Sponsor
- Shire
COVID-19
A Prospective, Phase II Study to Evaluate Safety of 101-PGC-005 ('005) for Moderate to Severe COVID-19 Disease Along With Standard of Care
In December 2019, a novel pneumonia caused by a previously unknown pathogen emerged in Wuhan, China. The pathogen was soon identified as a novel coronavirus (SARS-CoV-2), which is closely related to severe acute respiratory…
- Trial name
- NCT05195749
- Testing
- 101-PGC-005 ('005) + SOC
- Where
- Israel
- Volunteers
- 3 people
- Sponsor
- 101 Therapeutics
Ulcerative Colitis (UC)
A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy
Study M15-722 is a Phase 2a study to investigate the efficacy and safety of Ravagalimab (ABBV-323) in participants with moderate to severe UC who failed prior therapy.
- Trial name
- NCT03695185
- Testing
- Ravagalimab 600 mg, Ravagalimab 300 mg
- Where
- 34 sites in United States, Canada and 8 more
- Volunteers
- 42 people
- Sponsor
- AbbVie
Rheumatoid Arthritis (RA)
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs
The study objective of Period 1 was to compare the safety and efficacy of upadacitinib 15 mg once daily (QD) to abatacept on a background of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) for the…
- Trial name
- NCT03086343
- Testing
- Abatacept, Upadacitinib
- Where
- 161 sites in United States, Argentina and 28 more
- Volunteers
- 657 people
- Sponsor
- AbbVie
Inflammatory Diseases
Study of Efavaleukin Alfa in Healthy Chinese, Japanese, and Caucasian Participants
The primary objective of this study is to evaluate the pharmacokinetics (PK) of efavaleukin alfa after single subcutaneous (SC) administration in healthy Chinese, Japanese, and Caucasian participants.
- Trial name
- NCT04987333
- Testing
- Efavaleukin alfa
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Amgen
Ulcerative Colitis
TP0502-Pharmaco-Scintigraphic-Study and Amendment
This is a Phase I, open-label, single-site trial to evaluate the drug release, using scintigraphic images and mesalazine plasma levels (PK) in healthy subjects and patients with mildly active UC.
- Trial name
- NCT02306785
- Testing
- TP05 Coating D, TP05 Coating E, TP05 Coating H
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Tillotts Pharma AG
Ulcerative Colitis
Open-label V565 Target Engagement Study
The purpose of the study is to confirm that V565 enters inflamed tissue, binds to TNF and reduces inflammation after oral dosing to patients with IBD.
- Trial name
- NCT03705117
- Testing
- V565
- Where
- United Kingdom
- Volunteers
- 5 people
- Sponsor
- VHsquared Ltd.
Healthy Participants, Atopic Dermatitis
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of escalating single and repeat doses of PF-07832837 in healthy participants and in participants with moderate to severe atopic dermatitis.
- Trial name
- NCT06564389
- Testing
- PF-07832837
- Where
- 5 sites in United States
- Volunteers
- 119 people, healthy volunteers welcome
- Sponsor
- Pfizer
Sepsis
SEP-SEQ Trial - Determining the Etiology of Sepsis Using an Infectious Disease Diagnostic Sequencing Assay
The purpose of this study is to evaluate the performance of the Karius Infectious Diseases Plasma Sequencing Assay in patients who present to the emergency room with sepsis.
- Trial name
- NCT02730468
- Where
- United States
- Volunteers
- 350 people
- Sponsor
- Karius, Inc.
Osteoarthritis, Inflammatory Arthritis
Gender Solutions Natural Knee Post-Market Study
This is a prospective multicenter study of the Gender Solutions Natural Knee Flex System when used in primary total knee arthroplasty.
- Conditions
- Osteoarthritis, Inflammatory Arthritis, Post-traumatic Arthritis, Rheumatoid Arthritis
- Trial name
- NCT01463566
- Testing
- Zimmer Gender(R) Solutions(TM) Natural-Knee(R) Flex System
- Sponsor
- Zimmer Biomet
Hidradenitis Suppurativa
Efficacy and Safety of Olatorepatide Versus Placebo in Adults With Moderate to Severe Hidradenitis Suppurativa Living With Overweight or Obesity
This study will test an experimental Regeneron drug called olatorepatide ("study drug") to see if it can help treat Hidradenitis Suppurativa (HS).
- Trial name
- NCT07830329
- Testing
- Olatorepatide
- Volunteers
- 300 people
- Sponsor
- Regeneron Pharmaceuticals
Pouchitis
Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis
This is an open-label pilot study in which all patients will receive AST-120 for 4 weeks. Patients will discontinue antibiotics at study entry.
- Trial name
- NCT00583531
- Testing
- AST-120
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Ocera Therapeutics
Crohn's Disease, Fistula
Follow-up Study of Autologous Cultured Adipose-derived Stem Cells for the Crohn's Fistula
This is an open follow-up clinical trials to evaluate a sustained efficacy and safety of Adipoplus inj. for 10 months (12 months after final dose injection)after Phase II clinical trial.
- Trial name
- ANTG-ASC-203 (NCT01314079)
- Where
- 3 sites in South Korea
- Volunteers
- 37 people
- Sponsor
- Anterogen Co., Ltd.
Crohn's Disease
Safety and Immunogenicity of a TNFa Kinoid in Patients With Crohn's Disease
Evaluation of the safety and the immune response induced by active immunization through a TNFa kinoid in patients with Crohn's disease.
- Trial name
- NCT00808262
- Testing
- TNFa Kinoid
- Where
- 6 sites in South Africa, Switzerland
- Volunteers
- 21 people
- Sponsor
- Neovacs
Crohn Disease
A Study of TAK-018 in Preventing the Recurrence of Crohn's Disease After Surgery
The main aim is to see if TAK-018 reduces the recurrence of intestinal inflammation after abdominal resection surgery in adults with Crohn's disease.
- Trial name
- NCT03943446
- Testing
- TAK-018
- Where
- 41 sites in United States, Austria and 3 more
- Volunteers
- 34 people
- Sponsor
- Takeda
Ankylosing Spondylitis
Study to Examine the Clinical Efficacy and the Nonsteroidal Anti-inflammatory Drug (NSAID)-Sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis
This study assessed the clinical Assessment of SpondyloArthritis international Society (ASAS) 20 response to secukinumab and evaluated to which extent concomitant nonsteroidal anti-inflammatory drug (NSAID) treatment can be…
- Trial name
- ASTRUM (NCT02763046)
- Testing
- Secukinumab (AIN457) 150 mg s.c.
- Where
- 39 sites in Germany
- Volunteers
- 211 people
- Sponsor
- Novartis Pharmaceuticals
Granulomatous Colitis, Crohn's Disease
An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease
The purpose of this study is to assess the safety and effectiveness of BMS-986165 compared to placebo in participants with moderately to severely active Crohn's Disease.
- Conditions
- Granulomatous Colitis, Crohn's Disease, Crohn's Enteritis, Granulomatous Enteritis
- Trial name
- NCT03599622
- Testing
- BMS-986165
- Where
- 259 sites in United States, Australia and 24 more
- Volunteers
- 239 people
- Sponsor
- Bristol-Myers Squibb
Sub-healthy, Hyperlipidemia
The Exploratory Study About the Effect of Using Double Filtration Plasmapheresis (DFPP) Removing Inflammatory Cytokines, Lipids and Toxic Metal Ions in Peripheral Blood in Adults
This study investigates whether using Double Filtration Plasmapheresis (DFPP) could improve the overall health of adults through removing inflammatory cytokines, lipids and toxic metal ions from peripheral blood.
- Conditions
- Sub-healthy, Hyperlipidemia, Toxic Metal Ions Accumulation
- Trial name
- NCT06224296
- Testing
- DFPP
- Where
- China
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Shanghai Cell Therapy Group Co.,Ltd
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.